AKT1 (Ab-326) Antibody

What is AKT1 and what cellular functions does it regulate?

AKT1 is one of three closely related serine/threonine-protein kinases (AKT1, AKT2, and AKT3) that constitute the AKT kinase family. It mediates numerous processes including metabolism, proliferation, cell survival, growth, and angiogenesis through phosphorylation of downstream substrates. Over 100 substrate candidates have been identified for AKT kinases. AKT1 plays a crucial role in the regulation of glucose uptake by mediating insulin-induced translocation of the SLC2A4/GLUT4 glucose transporter to the cell surface. It also regulates many processes related to cell survival and growth through multiple signaling pathways and is critical for neuronal survival, excitability, and synaptic plasticity. Animal studies have demonstrated that AKT1 knockout mice exhibit growth retardation, highlighting its importance in development .

What are the key specifications of the AKT1 (Ab-326) Antibody?

The AKT1 (Ab-326) Antibody is a rabbit polyclonal antibody that detects endogenous levels of total AKT protein. It was developed using a synthesized non-phosphopeptide derived from human AKT around the phosphorylation site of tyrosine 326 (N-D-Y(p)-G-R). The antibody is supplied in liquid form containing rabbit IgG in phosphate buffered saline (without Mg2+ and Ca2+), pH 7.4, 150mM NaCl, 0.02% sodium azide, and 50% glycerol. It has been affinity-purified from rabbit antiserum using epitope-specific immunogen-based affinity chromatography. The antibody demonstrates reactivity with Human, Mouse, and Rat samples and is identified with the UniProt number P31749 .

What experimental applications is the AKT1 (Ab-326) Antibody validated for?

The antibody has been validated for multiple experimental applications with specific recommended dilutions:

The antibody has been successfully used to detect AKT1 in various experimental systems including insulin-stimulated NIH/3T3 cells and human breast carcinoma tissue .

How can researchers differentiate between AKT isoforms when using AKT1 (Ab-326) Antibody?

Distinguishing between AKT isoforms requires strategic experimental approaches:

• Comparative isoform analysis: Use AKT1 (Ab-326) Antibody alongside isoform-specific antibodies to compare expression patterns. In Western blot analysis, AKT1 typically appears at approximately 56 kDa.

• Knockout cell line controls: Studies have utilized AKT1-/-, AKT2-/-, and AKT1-/-AKT2-/- cells to distinguish isoform-specific signals. Research shows that in HCT116 AKT1-/- cells, AKT2 consists of two dominant and one minor peak, while in AKT2-/- cells, AKT1 runs as six distinct peaks in native isoelectric focusing analysis .

• Native isoelectric focusing (NIA): This technique reveals distinctive patterns for each isoform. In NIA studies with a pan-AKT antibody, wild-type cells showed eight major peaks representing both AKT1 and AKT2. These patterns can be reconstituted by combining peaks from knockout cells, validating this approach for isoform identification .

• Phosphorylation pattern analysis: Each AKT isoform displays unique phosphorylation patterns that can help in identification when using phospho-specific antibodies in conjunction with total AKT1 antibodies .

• Functional validation: Since AKT isoforms have distinct roles (AKT1 in growth, AKT2 in metabolism, AKT3 in brain development), correlating antibody signals with functional outcomes can provide additional confirmation of isoform identity .

What methodologies can best characterize AKT1 phosphorylation dynamics?

To effectively study AKT1 phosphorylation dynamics:

• Combined antibody approach: Use AKT1 (Ab-326) Antibody alongside phospho-specific antibodies (e.g., pThr308, pSer473, pThr450, pSer124) to provide a comprehensive view of phosphorylation status.

• Mutational analysis: Create non-phosphorylatable mutants (T308A, S473A, T450A, S124A) to study specific phosphorylation sites. Research has shown that T308A and S473A mutations significantly reduce cell invasion capabilities, indicating these sites are critical for this function .

• Phosphatase treatment controls: Treating cell lysates with phosphatase shifts the majority of AKT1 into a single peak at pI 5.75 in native isoelectric focusing, representing unphosphorylated AKT1. This serves as an important control for phosphorylation studies .

• Time-course stimulation experiments: Stimulate cells with growth factors (insulin, IGF-1) for various durations to observe phosphorylation kinetics. For example, insulin treatment (0.01U/ml for 15 minutes) has been shown to effectively activate AKT1 phosphorylation in NIH/3T3 cells .

• Quantitative assessment: Calculate the ratio of specific phosphorylated forms to total AKT1 to determine the extent of activation. Research has shown that approximately 47% of AKT1 becomes phosphorylated at Thr308 and 52% at Ser473 after insulin stimulation .

How can AKT1 (Ab-326) Antibody be utilized in studying AKT1's role in disease models?

For disease model applications:

• Cancer research: The antibody has been validated for detecting AKT1 in breast carcinoma tissues by immunohistochemistry. Aberrant AKT activation is prevalent across multiple human cancer lineages, making it an important therapeutic target .

• Kidney disease models: In unilateral ureteral obstruction (UUO) models, researchers can compare AKT1 expression between control and experimental kidneys. Studies show that AKT1-mediated muscle growth reduces renal damage in this model through increased eNOS signaling in the kidney .

• Schizophrenia research: Studies have implicated AKT1 in schizophrenia through association studies and decreased protein expression in patients' brains. The antibody can be used to examine AKT1 expression in post-mortem brain tissue or lymphocyte-derived cell lines from patients versus controls .

• Skeletal muscle studies: In skeletal muscle-specific, inducible AKT1 transgenic mouse models, the antibody can verify AKT1 activation. Research demonstrates that AKT1-mediated muscle growth promotes functional skeletal muscle independent of exercise .

• Integrin activation and matrix research: The antibody can be used to confirm AKT1 expression status when studying how AKT1 regulates integrin activation, matrix recognition, and fibronectin assembly in fibroblasts and endothelial cells .

What are the critical factors for optimizing Western blot results with AKT1 (Ab-326) Antibody?

For optimal Western blot performance:

• Sample preparation: Include phosphatase inhibitors in lysis buffers to preserve phosphorylation states. For activation studies, stimulate cells with insulin (0.01U/ml for 15 minutes) before lysis to enhance phosphorylation signals .

• Dilution optimization: Begin with a 1:1000 dilution and adjust within the recommended 1:500-1:3000 range based on signal strength. Western blot analysis of extracts from NIH/3T3 cells, HeLa cells, and 293 cells has been successfully performed at these dilutions .

• Blocking conditions: Use 5% BSA or non-fat milk in TBST for 1 hour at room temperature to minimize background. For phospho-specific detection, BSA is preferred over milk as milk contains casein phosphoproteins that may interfere with phospho-antibody binding.

• Incubation parameters: Incubate with primary antibody overnight at 4°C for optimal binding, followed by appropriate HRP-conjugated secondary antibody (anti-rabbit IgG) for 1 hour at room temperature.

• Specificity controls: Include a lane treated with synthesized peptide as a competition control. Research has shown that pre-incubation with the immunizing peptide effectively blocks specific binding, as demonstrated in Western blot analysis of extracts from HeLa and 293 cells .

What controls are essential when using AKT1 (Ab-326) Antibody in immunohistochemistry and immunofluorescence?

Essential controls include:

• Positive tissue controls: Human breast carcinoma tissue for IHC and HeLa cells for IF have been validated as appropriate positive controls .

• Negative controls:

  • Primary antibody omission control

  • Isotype control (rabbit IgG at equivalent concentration)

  • AKT1 knockout tissues/cells where available

• Peptide competition control: Pre-incubate the antibody with its immunizing peptide to confirm binding specificity. This approach has been successfully demonstrated in Western blot analysis and can be adapted for IHC/IF applications .

• Phosphorylation controls: When studying phosphorylation states, include samples treated with phosphatase to establish baseline expression.

• Stimulation controls: For activation studies, include both unstimulated and stimulated samples (e.g., with insulin) to demonstrate the dynamic range of AKT1 activation .

How should researchers design experiments to study the relationship between AKT1 and integrin signaling?

For investigating AKT1-integrin relationships:

• Comparative cellular models: Utilize wild-type and AKT1-/- cells to assess differences in integrin activation and matrix recognition. Research has demonstrated that AKT1 is essential for the inside-out activation of integrins in endothelial cells and fibroblasts .

• Integrin activation assessment: Employ antibodies specific for active integrin conformations (e.g., WOW-1 for active β1 integrin) alongside AKT1 (Ab-326) Antibody to correlate AKT1 expression with integrin activation status .

• Matrix assembly experiments: Add exogenous fibronectin (10 μg) to cell cultures and analyze matrix assembly with and without AKT inhibitors. Studies show that PI3K inhibitors (10 μM LY294002) and AKT inhibitors (1 μM SH-5) can affect fibronectin matrix assembly .

• Gain-of-function approaches: Use NIH 3T3 fibroblasts expressing various forms of AKT1 (wild-type, constitutively active myrAKT1, or dominant-negative DN-AKT1) to assess how different AKT1 activity states affect integrin-mediated functions .

• Migration assays: Perform wound healing or transwell migration assays to correlate AKT1 activation with cell migration capabilities. Research has shown that AKT1 influences extracellular matrix recognition and migration of endothelial cells .

What are the most common technical issues when using AKT1 (Ab-326) Antibody and how can they be resolved?

Common issues and solutions:

• High background in Western blot:

  • Increase blocking time or concentration

  • Reduce primary antibody concentration (try 1:3000 dilution)

  • Perform more stringent washing (additional TBST washes)

  • Use fresh blocking reagents

• Weak or no signal:

  • Increase protein loading (30-50 μg per lane)

  • Use a more concentrated antibody dilution (1:500)

  • Extend primary antibody incubation time (overnight at 4°C)

  • Verify transfer efficiency with Ponceau S staining

  • Check sample handling to prevent protein degradation

• Multiple bands or unexpected patterns:

  • AKT1 has multiple phosphorylation states that may appear as different bands

  • Review the literature on AKT1 migration patterns in native isoelectric focusing, which shows AKT1 can appear as 6 peaks in AKT2-/- cells

  • Verify with knockout controls or peptide competition

• Storage-related issues:

  • Upon receipt, store at -20°C or -80°C as recommended

  • Avoid repeated freeze-thaw cycles by preparing small aliquots

  • Monitor expiration dates and storage conditions

How can researchers accurately interpret complex phosphorylation patterns of AKT1?

For accurate interpretation of phosphorylation patterns:

• Multiple phosphorylation site analysis: Research has identified several key phosphorylation sites on AKT1 with distinct functional implications. Thr308 and Ser473 phosphorylation are critical for cell invasion, while Thr450 affects protein stability and Ser124 influences optimal cell invasion .

• Phosphorylation site interdependence: Studies show that phosphorylation events can be uncoupled—pThr308 and pSer473 antibodies identified distinct subsets of AKT1 molecules, indicating these modifications can occur independently in some AKT1 molecules .

• Native isoelectric focusing interpretation: Under serum starvation conditions, AKT1 presents as 4 major peaks (pI 5.29, 5.40, 5.50, and 5.60) and 5 minor peaks (pI 5.22, 5.35, 5.44, 5.53, and 5.75). Phosphatase treatment shifts most AKT1 to a single peak at pI 5.75, representing unphosphorylated AKT1 .

• Quantitative assessment: After insulin stimulation, approximately 47% of AKT1 becomes phosphorylated at Thr308 and 52% at Ser473. The lower pI peaks (5.20 or below) contain the majority of phosphorylated AKT1 (~70% of pThr308 and ~67% of pSer473) .

• Mutational analysis comparison: Non-phosphorylatable mutants (T308A, S473A, T450A, S124A) show distinct migration patterns and functional effects, providing reference points for interpreting wild-type phosphorylation patterns .

What considerations are important when using AKT1 (Ab-326) Antibody across different cell types and tissues?

Important cross-tissue considerations:

How can AKT1 (Ab-326) Antibody contribute to understanding AKT1's role in muscle-kidney crosstalk?

AKT1 (Ab-326) Antibody can provide valuable insights into muscle-kidney interactions:

• Transgenic model analysis: In skeletal muscle-specific, inducible AKT1 transgenic mouse models, the antibody can verify AKT1 activation in muscle tissue. Research shows that AKT1-mediated muscle growth reduces renal damage in obstructive kidney disease models .

• Signaling pathway investigation: Studies demonstrate that an increase in the activating phosphorylation of endothelial Nitric Oxide Synthase (eNOS) in the kidney accompanies the attenuation of renal damage by myogenic AKT1 activation. The antibody can help track AKT1 expression in both muscle and kidney tissues to understand this cross-tissue signaling .

• Disease marker correlations: In unilateral ureteral obstruction (UUO) models, wild-type mice show upregulation of atrogin-1 (an atrophy-inducing gene) in skeletal muscle 7 days after UUO, while AKT1 transgenic mice do not. The antibody can monitor AKT1 expression in relation to muscle atrophy markers .

• Intervention studies: When treatments like NOS inhibitor L-NAME are used to abolish the protective effect of skeletal muscle AKT activation on obstructive kidney disease, the antibody can track corresponding changes in AKT1 expression and activation .

• Clinical correlation research: Since muscle wasting is frequently observed in patients with kidney disease, and low muscle strength is associated with poor outcomes, the antibody can help investigate the molecular mechanisms connecting muscle maintenance with kidney function .

What approaches can researchers use to study AKT1's role in phosphorylation-dependent protein interactions?

To study phosphorylation-dependent interactions:

• Phosphorylation-specific interaction mapping: Use AKT1 (Ab-326) Antibody alongside phospho-specific antibodies to correlate specific phosphorylation states with protein-protein interactions. Research shows that AKT1 has multiple phosphorylation states that may influence its interaction partners .

• Mutational analysis: Create non-phosphorylatable mutants (T308A, S473A, T450A, S124A) and phosphomimetic mutants to study how specific phosphorylation sites affect protein interactions. Studies demonstrate that these mutations have distinct effects on AKT1 function and stability .

• Native complex isolation: Use the antibody for immunoprecipitation followed by mass spectrometry to identify interaction partners of differently phosphorylated AKT1 pools.

• Functional correlation studies: Compare phosphorylation status with downstream substrate activation. For example, T308A mutation abrogates insulin-induced PRAS40 phosphorylation, indicating this site is critical for AKT1's ability to phosphorylate PRAS40 .

• Temporal dynamics analysis: Track the relationship between AKT1 phosphorylation and the formation/dissolution of protein complexes over time after stimulation with insulin or growth factors.

How can AKT1 (Ab-326) Antibody be applied to study AKT1's role in integrin-mediated matrix assembly?

For studying integrin-mediated matrix assembly:

• Fibronectin assembly assays: Add exogenous fibronectin (10 μg) to cell cultures with and without AKT inhibitors to analyze matrix assembly patterns. Research demonstrates that AKT1 is essential for integrin activation, which in turn mediates matrix assembly by fibroblasts .

• Inside-out signaling analysis: Use AKT1 (Ab-326) Antibody to correlate AKT1 expression with integrin activation status. Studies show that AKT1 is necessary for the inside-out activation of integrins in endothelial cells and fibroblasts .

• Gain- and loss-of-function approaches: Compare wild-type cells with those expressing different AKT1 variants (constitutively active, dominant negative) or AKT1-/- cells to assess effects on matrix assembly. This approach has been used to delineate the importance of AKT1 in controlling matrix recognition and fibronectin assembly .

• Integrin activation measurement: Use integrin β1-stimulating antibodies, blocking antibodies, and antibodies that detect only the active form of integrin β1 alongside AKT1 (Ab-326) Antibody to demonstrate that AKT1-mediated effects occur via the ability of AKT1 to activate integrin β1 .

• Matrix recognition experiments: Assess the ability of cells with different AKT1 activity states to adhere and migrate on different matrix proteins. Research shows that AKT1 signaling regulates extracellular matrix recognition and migration of endothelial cells .